Effects of verapamil on (Na+ + K+)-ATPase, Ca2+-ATPase, and adenylate cyclase activity in a membrane fraction from rat and guinea pig ventricular muscle.
The electrophysiologic properties and the negative inotropic effect of verapamil are most likely due to the inhibition of calcium movement across the sarcolemmal membrane. A possible biochemical basis for this inhibition of calcium movement was studied in a membrane fraction rich in (Na+ + K+)-ATPase (EC 3.6.1.3) and adenylate cyclase (EC 4.6.1.1) activity and which demonstrated Ca2+-ATPase (EC 3.6.1.3) activity. Since each of these enzymes has the potential for influencing transsarcolemmal calcium movements, the effect of verapamil on their activities was studied in this membrane fraction isolated from rat and guinea pig hearts. Ca2+-ATPase activity in the rat was 37.7 mumol Pi/mg per hour compared with 13.8 +/- 2.9 in the guinea pig (p less than 0.01). Corresponding values for (Na+ + k+)-atpase activites were 7.9 +/- 0.9 mumol Pi/mg per hour versus 10.2 +/- 1.4. Adenylate cyclase activity in the rat was 240 +/- 8 pmol/mg per minute compared with 299 +/- 27. It was found that verapamil in concentrations of 0.01-100 mg/litre (2.1 X 10(-8) to 2.1 X 10(-4) M) had no effect on the activity of the above enzymes in either species and it was concluded that a biochemical basis for the effect of verapamil on calcium flux has yet to be defined.
D000251:Adenosine Triphosphatases / Q000378:metabolism*; D000262:Adenylyl Cyclases / Q000378:metabolism*; D000818:Animals; D002118:Calcium / Q000378:metabolism; D006168:Guinea Pigs; D009206:Myocardium / Q000201:enzymology* / Q000648:ultrastructure; D010042:Ouabain / Q000378:metabolism; D011188:Potassium / Q000378:metabolism; D051381:Rats; D012508:Sarcolemma / Q000201:enzymology; D012964:Sodium / Q000378:metabolism; D013045:Species Specificity; D014700:Verapamil / Q000494:pharmacology*
D010042:Ouabain; D012964:Sodium; D014700:Verapamil; D000251:Adenosine Triphosphatases; D000262:Adenylyl Cyclases; D011188:Potassium; D002118:Calcium